Maze Therapeutics, Inc. (MAZE) Institutional Ownership

Ownership Summary

Maze Therapeutics, Inc. (NASDAQ:MAZE) currently has 24 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The collective stake of institutional investors in Maze Therapeutics moved to 11.0% in December 2025, a shift down from the 169.4% reported for September 2025.
• The company experienced a 33.54% quarterly change in institutional shares held, alongside an unavailable change in total owners annually.
• The latest 13F cycle for Maze Therapeutics reveals that of 24 total investors, 20 funds grew their exposure, whereas 2 reduced theirs and 2 made no changes.
• This class of investors increased its holdings in Maze Therapeutics to 2.78Mn shares for the 13F-cycle ending December 2025, up by 698.61K shares quarter on quarter, and down N/A shares year over year.
• VANGUARD GROUP INC continues to be the largest institutional holder of Maze Therapeutics as of December 31, 2025, with a position of 1.70Mn shares, representing 6.69% of the company's outstanding stock.
• Among the most significant buyers of Maze Therapeutics during December 2025 were VANGUARD GROUP INC (362.06K), Mass General Brigham, Inc (239.99K), WASHINGTON UNIVERSITY (70.12K), Falcon Wealth Planning (10.03K), China Universal Asset Management Co., Ltd. (9.44K).
• Leading sellers of Maze Therapeutics stock in December 2025 included STRS OHIO (6.70K), Farther Finance Advisors, LLC (24).
• The top 10 institutional holders of Maze Therapeutics for the quarter ending December 2025 included VANGUARD GROUP INC (1.70Mn), BESSEMER GROUP INC (481.79K), WASHINGTON UNIVERSITY (280.80K), Mass General Brigham, Inc (239.99K), UBS Group AG (28.70K), China Universal Asset Management Co., Ltd. (11.44K), STRS OHIO (11.20K), Falcon Wealth Planning (10.03K), SG Americas Securities, LLC (8.49K), WestHill Financial Advisors, Inc. (5.19K).